Host-response therapeutics for periodontal diseases

Journal of Periodontology

Volumn 79, Issue 8 SUPPL., 2008, Pages 1592-1600

  Giannobile, William V ^a,b  

^a Michigan Center for Oral Health Research   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bisphosphonates; Bone resorption; Matrix metalloproteinases; Periodontitis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CATHEPSIN; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE;

CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFECT; GRAM NEGATIVE INFECTION; HOST PATHOGEN INTERACTION; HUMAN; MICROBIOLOGY; PERIODONTAL DISEASE;

BONE DENSITY CONSERVATION AGENTS; CATHEPSINS; DIPHOSPHONATES; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; MATRIX METALLOPROTEINASES; PERIODONTAL DISEASES; TETRACYCLINES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 49449106328     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.080174     Document Type: Conference Paper

References (40)

1. Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Ann N Y Acad Sci 2007;1098:230-251.
2. Albandar JM. Periodontal diseases in North America. Periodontol 2000 2002;29:31-69.
3. Woodward JK, Holen I, Coleman RE, Buttle DJ. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone 2007;41:912-927.
4. Pussinen PJ, Paju S, Mantyla P, Sorsa T. Serum microbial- and host-derived markers of periodontal diseases: A review. Curr Med Chem 2007;14:2402-2412.
5. auf dem Keller U, Doucet A, Overall CM. Protease research in the era of systems biology. Biol Chem 2007;388:1159-1162.
6. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007;26:587-596.
7. Tester AM, Cox JH, Connor AR, et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2007;2:e312.
8. Gill SE, Parks WC. Metalloproteinases and their inhibitors: Regulators of wound healing. Int J Biochem Cell Biol 2007;40:1334-1347.
9. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-808.
10. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006;38:306-321.
11. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997;46:310-319.
12. Herr AE, Hatch AV, Giannobile WV, et al. Integrated microfluidic platform for oral diagnostics. Ann N Y Acad Sci 2007;1098:362-374.
13. Herr AE, Hatch AV, Throckmorton DJ, et al. Microfluidic immunoassays as rapid saliva-based clinical diagnostics. Proc Natl Acad Sci USA 2007;104:5268-5273.
14. Kinane DF, Darby IB, Said S, et al. Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance. J Periodontal Res 2003;38:400-404.
15. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;43:294-315.
16. Golub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical "two-hit" model. J Dent Res 2006;85:102-105.
17. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992;2:80-90.
18. Williams RC. Periodontal disease. N Engl J Med 1990;322:373-382.
19. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.
20. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci 1999;878:335-346.
21. Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998;12:27-31.
22. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
23. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
24. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008;79:440-452.
25. Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: A proof of concept trial. J Periodontol 2004;75:441-452.
26. Payne JB, Stoner JA, Nummikoski PV, et al. Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women. J Clin Periodontol 2007;34:776-787.
27. Reinhardt RA, Stoner JA, Golub LM, et al. Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: Clinical outcomes. J Clin Periodontol 2007;34:768-775.
28. Golub LM, Lee HM, Stoner JA, et al. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008;79:1409-1418.
29. Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 2007;13:2087-2100.
30. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73:813-822.
31. Kamel HK. Update on osteoporosis management in long-term care: Focus on bisphosphonates. J Am Med Dir Assoc 2007;8:434-440.
32. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, Norton LA, eds. Biological Mechanisms of Tooth Movement and Craniofacial Adaptation,vol. 1. Cambridge, MA: Harvard Society for the Advancement of Orthodontics; 1996:365-373.
33. Rocha M, Nava LE, Vázquez de la Torre C, Sánchez-Marin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;72:204-209.
34. Takaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: Report of four cases. J Int Med Res 2001;29:355-365.
35. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76:1113-1122.
36. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol 2007;78:584-594.
37. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-1128.
38. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
39. Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw. Available at: http://www.fda.gov/OHRMS/DOCKETS/AC/ 05/briefing/2005-4095B2_02_12-Novartis-Zometa-App-11.pdf. Accessed January 23, 2008.
40. American Academy of Periodontology. AAP statement on bisphosphonates. http://www.perio.org/resourcesproducts/bisphosphonates.htm. Published 2005. Accessed May 30, 2008.